Celebration of the fourth Anniversary of Tengsheng Boyao: spring and autumn, ready to go

$BRII-B (02137.HK)$Tengsheng Boyao Biotechnology Co., Ltd. ("Tengsheng Boyao" 2137.HK) is a biotech company based in China and the United States. It is committed to developing innovative treatments for major infectious diseases in China and around the world, such as hepatitis B, COVID-19, human immunodeficiency virus (HIV) infection, multiple drug resistance (MDR) or extensively drug resistance (XDR) gram-negative bacteria infection, and other diseases with significant public health burden, such as central nervous system (CNS) diseases.